MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities

Authors

Kang Qin
Lingzhi Hong
Jianjun Zhang
Xiuning Le

Publication Date

1-18-2023

Journal

Cancers

DOI

10.3390/cancers15030612

PMID

36765572

PMCID

PMC9913224

PubMedCentral® Posted Date

1-18-2023

PubMedCentral® Full Text Version

Post-print

Abstract

Targeted therapy has emerged as an important pillar for the standard of care in oncogene-driven non-small cell lung cancer (NSCLC), which significantly improved outcomes of patients whose tumors harbor oncogenic driver mutations. However, tumors eventually develop resistance to targeted drugs, and mechanisms of resistance can be diverse.

Published Open-Access

yes

Recommended Citation

Qin, Kang; Hong, Lingzhi; Zhang, Jianjun; et al., "MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities" (2023). Faculty, Staff and Student Publications. 4156.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4156